12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Embeda regulatory update

FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) issued a warning letter to King citing two video news releases promoting Embeda extended-release morphine/naltrexone. The agency said the videos...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >